Literature DB >> 29325618

Neurodegeneration with brain iron accumulation.

Susan J Hayflick1, Manju A Kurian2, Penelope Hogarth3.   

Abstract

Neurodegeneration with brain iron accumulation (NBIA) comprises a clinically and genetically heterogeneous group of disorders affecting children and adults. These rare disorders are often first suspected when increased basal ganglia iron is observed on brain magnetic resonance imaging. For the majority of NBIA disorders the genetic basis has been delineated, and clinical testing is available. The four most common NBIA disorders include pantothenate kinase-associated neurodegeneration (PKAN) due to mutations in PANK2, phospholipase A2-associated neurodegeneration caused by mutation in PLA2G6, mitochondrial membrane protein-associated neurodegeneration from mutations in C19orf12, and beta-propeller protein-associated neurodegeneration due to mutations in WDR45. The ultrarare NBIA disorders are caused by mutations in CoASY, ATP13A2, and FA2H (causing CoA synthase protein-associated neurodegeneration, Kufor-Rakeb disease, and fatty acid hydroxylase-associated neurodegeneration, respectively). Together, these genes account for disease in approximately 85% of patients diagnosed with an NBIA disorder. New NBIA genes are being recognized with increasing frequency as a result of whole-exome sequencing, which is also facilitating early ascertainment of patients whose phenotype is often nonspecific.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BPAN; INAD; MPAN; NBIA; PKAN; PLAN; infantile neuroaxonal dystrophy; neurodegeneration with brain iron accumulation; pantothenate kinase

Mesh:

Substances:

Year:  2018        PMID: 29325618      PMCID: PMC8235601          DOI: 10.1016/B978-0-444-63233-3.00019-1

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  32 in total

1.  Racial hygiene, active euthanasia, and Julius Hallervorden.

Authors:  M Shevell
Journal:  Neurology       Date:  1992-11       Impact factor: 9.910

2.  Thirty neurological eponyms associated with the nazi era.

Authors:  Daniel Kondziella
Journal:  Eur Neurol       Date:  2009-04-30       Impact factor: 1.710

3.  Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation.

Authors:  Monika B Hartig; Arcangela Iuso; Tobias Haack; Tomasz Kmiec; Elzbieta Jurkiewicz; Katharina Heim; Sigrun Roeber; Victoria Tarabin; Sabrina Dusi; Malgorzata Krajewska-Walasek; Sergiusz Jozwiak; Maja Hempel; Juliane Winkelmann; Matthias Elstner; Konrad Oexle; Thomas Klopstock; Wolfgang Mueller-Felber; Thomas Gasser; Claudia Trenkwalder; Valeria Tiranti; Hans Kretzschmar; Gerd Schmitz; Tim M Strom; Thomas Meitinger; Holger Prokisch
Journal:  Am J Hum Genet       Date:  2011-10-07       Impact factor: 11.025

4.  Activation of human mitochondrial pantothenate kinase 2 by palmitoylcarnitine.

Authors:  Roberta Leonardi; Charles O Rock; Suzanne Jackowski; Yong-Mei Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-22       Impact factor: 11.205

5.  Rapid disease progression in adult-onset mitochondrial membrane protein-associated neurodegeneration.

Authors:  O Dogu; C E Krebs; H Kaleagasi; Z Demirtas; N Oksuz; R H Walker; C Paisán-Ruiz
Journal:  Clin Genet       Date:  2013-01-21       Impact factor: 4.438

6.  Novel histopathologic findings in molecularly-confirmed pantothenate kinase-associated neurodegeneration.

Authors:  Michael C Kruer; Mark Hiken; Allison Gregory; Alessandro Malandrini; David Clark; Penny Hogarth; Marjorie Grafe; Susan J Hayflick; Randall L Woltjer
Journal:  Brain       Date:  2011-04       Impact factor: 13.501

7.  Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN).

Authors:  M A Kurian; N V Morgan; L MacPherson; K Foster; D Peake; R Gupta; S G Philip; C Hendriksz; J E V Morton; H M Kingston; E M Rosser; E Wassmer; P Gissen; E R Maher
Journal:  Neurology       Date:  2008-04-29       Impact factor: 9.910

8.  Neurodegeneration associated with genetic defects in phospholipase A(2).

Authors:  A Gregory; S K Westaway; I E Holm; P T Kotzbauer; P Hogarth; S Sonek; J C Coryell; T M Nguyen; N Nardocci; G Zorzi; D Rodriguez; I Desguerre; E Bertini; A Simonati; B Levinson; C Dias; C Barbot; I Carrilho; M Santos; I Malik; J Gitschier; S J Hayflick
Journal:  Neurology       Date:  2008-09-17       Impact factor: 9.910

9.  ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation.

Authors:  Susanne A Schneider; Coro Paisan-Ruiz; Niall P Quinn; Andrew J Lees; Henry Houlden; John Hardy; Kailash P Bhatia
Journal:  Mov Disord       Date:  2010-06-15       Impact factor: 10.338

10.  PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron.

Authors:  Neil V Morgan; Shawn K Westaway; Jenny E V Morton; Allison Gregory; Paul Gissen; Scott Sonek; Hakan Cangul; Jason Coryell; Natalie Canham; Nardo Nardocci; Giovanna Zorzi; Shanaz Pasha; Diana Rodriguez; Isabelle Desguerre; Amar Mubaidin; Enrico Bertini; Richard C Trembath; Alessandro Simonati; Carolyn Schanen; Colin A Johnson; Barbara Levinson; C Geoffrey Woods; Beth Wilmot; Patricia Kramer; Jane Gitschier; Eamonn R Maher; Susan J Hayflick
Journal:  Nat Genet       Date:  2006-06-18       Impact factor: 38.330

View more
  35 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-24       Impact factor: 3.575

2.  Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders.

Authors:  Niels Bergsland; Eleonora Tavazzi; Ferdinand Schweser; Dejan Jakimovski; Jesper Hagemeier; Michael G Dwyer; Robert Zivadinov
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

3.  13-year diagnostic delay as cerebral palsy of an Iraqi patient with NBIA type 4.

Authors:  Ameer Shaker Hadi; Nebal Waill Saadi; Qusay Abed Fahad
Journal:  Neurol Clin Pract       Date:  2019-06

4.  Is Pallido-Pyramidal Syndrome Still a Useful Concept? No.

Authors:  Hugo Morales-Briceño; Victor S C Fung
Journal:  Mov Disord Clin Pract       Date:  2019-10-14

5.  Phenotypic and Imaging Spectrum Associated With WDR45.

Authors:  Laura A Adang; Amy Pizzino; Alka Malhotra; Holly Dubbs; Catherine Williams; Omar Sherbini; Anna-Kaisa Anttonen; Gaetan Lesca; Tarja Linnankivi; Chloé Laurencin; Matthieu Milh; Charles Perrine; Christian P Schaaf; Anne-Lise Poulat; Dorothee Ville; Tanner Hagelstrom; Denise L Perry; Ryan J Taft; Amy Goldstein; Arastoo Vossough; Ingo Helbig; Adeline Vanderver
Journal:  Pediatr Neurol       Date:  2020-03-11       Impact factor: 3.372

6.  Overdosing on iron: Elevated iron and degenerative brain disorders.

Authors:  Santosh R D'Mello; Mark C Kindy
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-02

7.  PARK14 (D331Y) PLA2G6 Causes Early-Onset Degeneration of Substantia Nigra Dopaminergic Neurons by Inducing Mitochondrial Dysfunction, ER Stress, Mitophagy Impairment and Transcriptional Dysregulation in a Knockin Mouse Model.

Authors:  Ching-Chi Chiu; Chin-Song Lu; Yi-Hsin Weng; Ying-Ling Chen; Ying-Zu Huang; Rou-Shayn Chen; Yi-Chuan Cheng; Yin-Cheng Huang; Yu-Chuan Liu; Szu-Chia Lai; Kun-Jun Lin; Yan-Wei Lin; Yu-Jie Chen; Chao-Lang Chen; Tu-Hsueh Yeh; Hung-Li Wang
Journal:  Mol Neurobiol       Date:  2018-08-08       Impact factor: 5.590

Review 8.  Iron in Health and Disease: An Update.

Authors:  Ashutosh Lal
Journal:  Indian J Pediatr       Date:  2019-09-13       Impact factor: 1.967

Review 9.  Animals in the Brain.

Authors:  Eoin Mulroy; Bettina Balint; Matthew E Adams; Tom Campion; Marcelo Merello; Kailash P Bhatia
Journal:  Mov Disord Clin Pract       Date:  2019-02-28

Review 10.  iPLA2β and its role in male fertility, neurological disorders, metabolic disorders, and inflammation.

Authors:  John Turk; Tayleur D White; Alexander J Nelson; Xiaoyong Lei; Sasanka Ramanadham
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-11-05       Impact factor: 4.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.